Inclusion completed

A phase II, multicenter, single-arm study of oral LDK378 in crizotinib naïve adult patients with ALK-activated non-small cell lung cancer

Cancer type: Lung cancer

Phase: II

Principal Investigator: Brunsvig Paal

Country: NO

Keywords: Norway, Oslo, ALK-activeted NSCLC, crizotinib

Status: Inclusion completed

Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01685138?term=2012-003474-36&rank=1